Analysts See $-0.07 EPS for CTI BioPharma Corp. (CTIC)

April 20, 2018 - By Adrian Erickson

CTI BioPharma Corp. (NASDAQ:CTIC) Logo

Analysts expect CTI BioPharma Corp. (NASDAQ:CTIC) to report $-0.07 EPS on May, 2.They anticipate $0.64 EPS change or 90.14 % from last quarter’s $-0.71 EPS. After having $-0.33 EPS previously, CTI BioPharma Corp.’s analysts see -78.79 % EPS growth. The stock increased 0.26% or $0.01 during the last trading session, reaching $3.89. About 69,054 shares traded. CTI BioPharma Corp. (NASDAQ:CTIC) has declined 7.09% since April 20, 2017 and is downtrending. It has underperformed by 18.64% the S&P500.

CTI BioPharma Corp. (NASDAQ:CTIC) Ratings Coverage

Among 3 analysts covering CTI BioPharma (NASDAQ:CTIC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CTI BioPharma had 3 analyst reports since February 23, 2018 according to SRatingsIntel. The rating was initiated by Needham on Monday, March 26 with “Buy”.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company has market cap of $225.55 million. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. It currently has negative earnings. The firm is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis.

CTI BioPharma Corp. (NASDAQ:CTIC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.